Department of Dermatology, University of Texas Southwestern Medical Center, Harry Hines, Dallas, TX, 75390, USA.
Department of Lung Transplant, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Arch Dermatol Res. 2024 Sep 11;316(8):612. doi: 10.1007/s00403-024-03284-7.
Solid organ transplant recipients (SOTRs) are at high risk of cutaneous squamous cell carcinoma (cSCC) metastasis. Despite prior studies identifying risk factors, mortality remains high. Understanding additional risk factors may aid in reducing mortality in this population. This study aimed to investigate risk factors and predictive variables for metastatic cSCC in SOTRs. The primary goal was to accurately identify transplant patients at increased risk of metastatic cSCC. A retrospective case-control study in a single institution of 3576 cases of organ transplants were identified from January 1991 to July 2022. A cohort of metastatic cancer patients and two randomly generated age and organ matched control cohorts were identified. 16 SOTR patients developed metastatic cSCC. The majority were male, with high-risk tumor sites. Tumor depth varied and half exhibited perineural invasion. Cylex® (p = 0.05) and white blood cell counts (p = 0.04) were significantly lower in these patients compared to control. Lung transplants were at highest risk relative to other solid organ transplants. Voriconazole exposure was also associated with increased metastatic risk (p = 0.04). Small sample size at a single institution. Close monitoring of SOTR, especially those with lung transplants given their increased risk, reducing immunosuppression, and limiting exposure to voriconazole can improve outcomes in SOTRs with metastatic cSCC.
实体器官移植受者(SOTR)患皮肤鳞状细胞癌(cSCC)转移的风险很高。尽管先前的研究确定了风险因素,但死亡率仍然很高。了解其他风险因素可能有助于降低该人群的死亡率。本研究旨在调查 SOTR 中转移性 cSCC 的风险因素和预测变量。主要目标是准确识别患有转移性 cSCC 的移植患者。对 1991 年 1 月至 2022 年 7 月期间在一家机构中进行的 3576 例器官移植的回顾性病例对照研究进行了研究。确定了转移性癌症患者队列和两个随机生成的年龄和器官匹配的对照组队列。有 16 名 SOTR 患者发生了转移性 cSCC。大多数为男性,具有高危肿瘤部位。肿瘤深度不同,有一半存在神经周围侵犯。与对照组相比,这些患者的 Cylex®(p=0.05)和白细胞计数(p=0.04)明显降低。与其他实体器官移植相比,肺移植的风险最高。伏立康唑暴露也与转移性风险增加相关(p=0.04)。研究样本量小,仅在一家机构进行。密切监测 SOTR,特别是那些肺移植患者,因为他们的风险增加,降低免疫抑制,限制伏立康唑暴露,可以改善患有转移性 cSCC 的 SOTR 的预后。